Since its inception in 1984, the TIMI Study Group has been an Academic Research Organization dedicated to advancing the knowledge and care of patients suffering from cardiovascular disease. We have led a wide array of trials, from phase I to phase IV, enrolling from less than 30 to more than 26,000 subjects, and with both industry and NIH support. Trials have been conducted in over 50 countries and at more than 5000 separate sites.
We investigate a broad array of therapeutic interventions in individuals across the spectrum of cardiovascular disease, ranging from prevention in those with risk factors, to emergent interventions in those with acute manifestations of disease. In addition, we have used our large database of clinical findings, biomarkers, and genotypes to enhance the understanding of cardiovascular disease and its risk factors.
By leading large-scale, international, randomized controlled trials of novel therapeutics and performing sophisticated analyses, we have been privileged to help shape the very practice of cardiovascular medicine for over a quarter of a century.
Recent News and Publications
6/3/2015 - New Publication: Cannon et al. Ezetimibe Added to Statin Therapy after Acute Coronary Syndromes. MORE
5/30/2015 - New Publication: O'Donoghue et al. Rationale and design of the LosmApimod To Inhibit p38 MAP kinase as a TherapeUtic target and moDify outcomes after an acute coronary syndromE trial. MORE
4/28/2015 - OSLER CV Outcomes Paper in NEJM recommended on F1000Prime MORE
4/28/2015 - VIDEO: PCSK9 Inhibitors: What to Know if They Come to Market MORE
03/24/2015 - VIDEO: New IMPROVE-IT analyses reinforce benefits of greater cholesterol reduction MORE